Home Featured Page 9

Featured

Latest

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

JOURNEYS: A Film Experience + Live Conversation with the Filmmakers

Psychedelic Policy Briefing: Week of July 20th, 2026

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic...

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on the GH-AtaiBeckley Patent Standoff; Field Reacts to FDA’s Guidance; Resilient Readies Resubmission

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

JOURNEYS: A Film Experience + Live Conversation with the Filmmakers

Psychedelic Policy Briefing: Week of July 20th, 2026

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on...

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research,...

Gov. Spencer Cox Signs Utah’s H.B. 390 Into Law, Authorizing Psychedelic...

ShroomskiCon 2026

Senate Bill S.4031 Signals a Federal Turn Toward Psychedelic Medicine

Psychedelic Culture 2026

TRYP EXPO

EDITOR PICKS

Pα+ Psychedelic Bulletin #228: Inside the Lilly-Atai Deal; An Update on...

Q3’26 Psychedelic Drug Development Pipeline: Bullseye Charts

The Vital Conference: Breckenridge 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY